STAT3 and cancer: Numerous efforts have been made over the last twenty years to develop small molecules to inhibit the STAT3 signaling axis; however, none have reached FDA approval for cancer treatment, underscoring the need for a better understanding of oncogenic STAT3 signaling mechanisms in order to develop an effective therapeutic approach [1,6,9,20].